Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacobus Pfisterer

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxelElfriede R Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, et al.
Virchows Archiv : an International Journal of Pathology|January 28, 2009
Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol)Stefan Kommoss, Dietmar Schmidt, Friedrich Kommoss, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 26, 2012
Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancerAndreas du Bois, Christian Marth, Jacobus Pfisterer, et al.
Gynecologic Oncology|August 15, 2006
Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxelRobert F Ozols, Michael A Bookman, Andreas du Bois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study GroupChristina Fotopoulou, Andreas duBois, Alexandros N Karavas, et al.
Auris, Nasus, Larynx|May 4, 2004
A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCCJan Bernd Weise, Steffen Maune, Tibor Görögh, et al.
Gynecologic Oncology|March 19, 2013
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCGFlorian Heitz, Andreas du Bois, Philipp Harter, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|December 25, 2007
No metastatic cervical adenocarcinomas in a series of p16INK4a-positive mucinous or endometrioid advanced ovarian carcinomas: an analysis of the AGO Ovarian Cancer Study GroupNicolas Wentzensen, Andreas du Bois, Stefan Kommoss, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 10, 2010
Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trialsElfriede R Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, et al.
Women'S Health (London, England)|September 2, 2011
Surgery for recurrent ovarian cancerFlorian Heitz, Andreas du Bois, Christian Kurzeder, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxelElfriede R Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, et al.
Virchows Archiv : an International Journal of Pathology|January 28, 2009
Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol)Stefan Kommoss, Dietmar Schmidt, Friedrich Kommoss, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 26, 2012
Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancerAndreas du Bois, Christian Marth, Jacobus Pfisterer, et al.
Gynecologic Oncology|August 15, 2006
Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxelRobert F Ozols, Michael A Bookman, Andreas du Bois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study GroupChristina Fotopoulou, Andreas duBois, Alexandros N Karavas, et al.
Auris, Nasus, Larynx|May 4, 2004
A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCCJan Bernd Weise, Steffen Maune, Tibor Görögh, et al.
Gynecologic Oncology|March 19, 2013
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCGFlorian Heitz, Andreas du Bois, Philipp Harter, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|December 25, 2007
No metastatic cervical adenocarcinomas in a series of p16INK4a-positive mucinous or endometrioid advanced ovarian carcinomas: an analysis of the AGO Ovarian Cancer Study GroupNicolas Wentzensen, Andreas du Bois, Stefan Kommoss, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 10, 2010
Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trialsElfriede R Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, et al.
Women'S Health (London, England)|September 2, 2011
Surgery for recurrent ovarian cancerFlorian Heitz, Andreas du Bois, Christian Kurzeder, et al.
Pageof 10